摘要
抗生素的耐药性升级减少了目前可用的抗菌药物的效用。这种威胁的一部分归因于药物的不良药代动力学和药效学。药物生产的改进是制药工业所面临的最具挑战性的任务,然而纳米技术可以给药物输送设计带来一场革命。纳米抗菌剂(NAMS)有其固有的抗菌活性(纳米颗粒)或增加附抗生素的总体疗效(纳米载体),从而有助于减轻或逆转耐药现象。纳米颗粒(NPs)具有自身固有的抗菌活性通过模仿由吞噬细胞即自然杀伤微生物杀灭,通过产生大量活性氧(ROS)和活性氮(RNS)。纳米颗粒通过同时作用于许多重要的生命过程或微生物的代谢途径来杀死微生物,以至于许多对它们产生抗性的基因突变似乎是不可能的。纳米载体改善封闭药物的药代动力学。此外,一个主要的技术,即纳米抗菌剂能克服阻力是有针对性的药物输送到病患部位。这篇综述是对纳米抗菌剂作用机制的综合背景中的多药耐药现象的综合总结。
关键词: 纳米抗菌药物,多药耐药,纳米颗粒,纳米载体系统,行动方式,活性氧(ROS)和活性氮(RNS)。
图形摘要
Current Drug Targets
Title:Mechanism of Action: How Nano-Antimicrobials Act?
Volume: 18 Issue: 3
Author(s): Bushra Jamil, Habib Bokhari, Mohammad Imran.
Affiliation:
关键词: 纳米抗菌药物,多药耐药,纳米颗粒,纳米载体系统,行动方式,活性氧(ROS)和活性氮(RNS)。
摘要: Escalating resistance to almost every class of antibiotics is reducing the utility of currently available antimicrobial drugs. A part of this menace is attributed to poor pharmacokinetics and pharmacodynamics of the drug. Improvement in drug delivery is the most challenging task encountered by the pharmaceutical industries; however nanotechnology can bring a revolution in drug delivery design. Nano-antimicrobials (NAMs) have their own intrinsic antimicrobial activity (nanoparticles) or augment overall efficacy of enclosed antibiotics (nano-carriers), thus contribute in mitigating or reversing the resistance phenomenon. Nano-particles (NPs) having their own intrinsic antimicrobial activity kill microbes by mimicking natural course of killing by phagocytic cells i.e., by producing large quantity of Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS). It is believed that NPs kill microbes by simultaneously acting on many essential life processes or metabolic routes of microbes; that as many genetic mutations to develop resistance against them seems to be impossible. Nano carriers improve the pharmacokinetics of the enclosed drug. Moreover, one of the major techniques by which NAMs can overcome resistance is targeted drug delivery to the site of disease. In this review, a comprehensive detail about the mechanism of action of NAMs are presented in context to multi drug resistance phenomenon.
Export Options
About this article
Cite this article as:
Bushra Jamil, Habib Bokhari, Mohammad Imran. , Mechanism of Action: How Nano-Antimicrobials Act?, Current Drug Targets 2017; 18 (3) . https://dx.doi.org/10.2174/1389450116666151019101826
DOI https://dx.doi.org/10.2174/1389450116666151019101826 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Nontuberculous Mycobacterium Infections in Rheumatoid Arthritis Patients: The Serodiagnosis of Pulmonary Disease due to Mycobacterium avium Complex with an Enzyme Immunoassay Kit Detecting Glycopeptidolipid Core Antigen (Capilia MAC Antibody ELISA)<sup>®</sup>)
Current Rheumatology Reviews AMPA Receptor Potentiators as Novel Antidepressants
Current Pharmaceutical Design Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Methicillin-Sensitive <i>Staphylococcus aureus</i> Pyogenic Iliopsoas Abscesses: A Case Series from Jodhpur, India
Infectious Disorders - Drug Targets Enhanced Production of Cholesterol Oxidase from Bacillus sp. COX-T<sub>3</sub> in a Biphasic System
Current Biotechnology Synthesis and Anti-tubercular Activity of 6-(<i>4</i>-Chloro/Methyl-phenyl)-4- Arylidene-4,5-dihydropyridazin-3(2<i>H</i>)-one Derivatives Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery 1,2,5-Thiadiazole Scaffold: A Review on Recent Progress in Biological Activities
Combinatorial Chemistry & High Throughput Screening Microwave: An Important and Efficient Tool for the Synthesis of Biological Potent Organic Compounds
Current Medicinal Chemistry Nicotinamide Supplementation Protects Gestational Diabetic Rats by Reducing Oxidative Stress and Enhancing Immune Responses
Current Medicinal Chemistry In Silico Assessment of Adverse Effects of a Large Set of 6-Fluoroquinolones Obtained from a Study of Tuberculosis Chemotherapy
Current Drug Safety Molecular Modeling Databases: A New Way in the Search of Protein Targets for Drug Development
Current Bioinformatics Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke
Current Medicinal Chemistry 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study
Current Topics in Medicinal Chemistry Linezolid - The First Oxazolidinone in the Treatment of Nosocomial MRSA Pneumonia
Recent Patents on Anti-Infective Drug Discovery Telemedicine, Genomics and Personalized Medicine: Synergies and Challenges
Current Pharmacogenomics and Personalized Medicine The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Association between the Use of Inhaled Corticosteroids and Pulmonary Nontuberculous Mycobacterial Infection: A Systematic Review
Current Respiratory Medicine Reviews A Note on the Potential BCG Vaccination – COVID-19 Molecular Link
Coronaviruses Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry